ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors
The market for antibody drug conjugates, or ADCs, is heating up, and the FDA on Monday sought to offer some guidance based on its past …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
